Short Attention Span? Shire Cited Again For Out-Of-Bounds ADHD Promotion
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA says that Intuniv patient materials claimed it treats such non-ADHD behavioral problems as temper outbursts.
You may also be interested in...
Jazz Buys Compliance Trouble With FazaClo Acquisition
The schizophrenia drug’s previous owner, Azur Pharma, produced a patient brochure that drew a warning letter FDA’s Office of Prescription Drug Promotion.
FDA Repulsed By Shire's Magnetic Promotion Of Vyvanse
DDMAC warning letter objects to a promotional magnet that obscures risk information; Bad Ad program draws attention to the tchotchke, which Shire stopped distributing in 2008.
FDA Repulsed By Shire's Magnetic Promotion Of Vyvanse
DDMAC warning letter objects to a promotional magnet that obscures risk information; Bad Ad program draws attention to the tchotchke, which Shire stopped distributing in 2008.